Partnerships

Gilead Sciences’ acquisition of Tubulis underscores the intensifying industry focus on antibody-drug conjugates as a key frontier in oncology treatment.

Merck is partnering with Infinimmune in a deal worth up to $838 million to leverage AI-driven antibody discovery.

The agreement grants Lilly an exclusive worldwide license to a portfolio of preclinical oral therapeutics.

Novartis and Otsuka Pharmaceutical are advancing deals to expand pipelines in allergy and psychiatry, with Novartis targeting next-generation anti-IgE therapy and Otsuka betting on a rapid-acting PTSD treatment.

The GSK licensing deal is reportedly worth up to $690 million.

Novo Nordisk partners with Vivtex Corporation to develop next-generation oral biologics for obesity and diabetes, while GSK agrees to acquire 35Pharma Inc. to expand its pulmonary hypertension pipeline.

AbbVie invests $380 million to build two new API manufacturing facilities in North Chicago while Bora Pharmaceuticals Co., Ltd. and GSK have renewed a five-year global manufacturing partnership.

A regulatory setback for Moderna’s next-generation flu vaccine underscores mounting scrutiny of late-stage trial design in the U.S., even as the company pivots to international manufacturing partnerships to sustain momentum in its respiratory franchise.

The collaboration will employ Iambi’s AI drug discovery technology to advance several small molecule programs in oncology, gastrointestinal, and inflammatory diseases.

Eli Lilly’s deals with Orna Therapeutics and Innovent Biologics helps structure Lilly's global development and commercialization in ways that balance regional expertise with worldwide scale.

The deal underscores a broader shift in autoimmune drug development toward therapies that aim to reprogram disease-driving immune responses at their source.

The acquisition includes several gummy products that are expected to begin launching in 2026.

Regulatory approval is no longer simply representative of the finish line—but instead can serve as a key launching point to evidence-driven insights that create more timely and broader product access.

Atkins is leveraging a partnership with reality TV star Heather Gay and early clinical trial data to reposition nutrition as a critical, science-backed complement to GLP-1 weight-loss therapies.

Shanghai Henlius used the 2026 J.P. Morgan Healthcare Conference to announce an exclusive global license for a potentially best-in-class anti-IL-1RAP monoclonal antibody that expands the company beyond oncology into high-unmet-need autoimmune and inflammatory diseases.

Johnson & Johnson reached a voluntary agreement with the U.S. government to enhance patient access, lower drug costs, and expand domestic manufacturing.

Lilly’s acquisition of Ventyx deepens its inflammation-focused pipeline with a strategic push to secure differentiated oral therapies aimed at chronic, immune-mediated diseases with significant unmet need.

GSK’s multi-year collaboration with Helix signals a push to embed genomics and real-world data into drug development, positioning precision medicine as a core engine for target discovery, clinical design, and long-term portfolio differentiation.

Sanofi and Earendil Labs' new collaboration pairs large-scale development capabilities with AI-driven protein discovery to accelerate next-generation bispecific therapies.

BioMarin’s $4.8 billion all-cash acquisition of Amicus Therapeutics significantly expands its rare disease portfolio with established Fabry and Pompe franchises, adds late-stage pipeline upside, and is expected to immediately accelerate revenue growth while strengthening long-term financial performance.

A pair of deal announcements underscore continued strategic reshuffling in biopharma, with Harbour BioMed striking a potentially billion-dollar collaboration with Bristol Myers Squibb to advance next-generation multispecific antibodies, while VYNE Therapeutics agreed to merge with Yarrow Bioscience to create a well-capitalized company focused on developing a first-in-class TSHR antibody for Graves’ disease and thyroid eye disease.

The agreement grants Sanofi with development and commercialization rights for ADEL-Y0, a potential first-in-class antibody therapy for Alzheimer's disease, and related backup compounds.

Lunit’s new collaboration with Daiichi Sankyo integrates AI-driven digital pathology tools into oncology translational research, aiming to accelerate biomarker discovery, refine patient stratification, and improve the efficiency of clinical development

Sobi’s $1.5 billion acquisition of Arthrosi Therapeutics positions the company for long-term growth and strengthens its gout treatment portfolio.

A successful transition from clinical development to commercial launch in cell and gene therapy requires early, structured collaboration with health systems to address operational, financial, and workflow challenges that shape real-world patient access and therapy adoption.